Therapeutic Response

dMMR status confers therapeutic sensitivity to Carboplatin in combination with Durvalumab and Paclitaxel in patients with Endometrial Carcinoma.

Statements

Source and description
Imfinzi (durvalumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to durvalumab in combination with carboplatin and paclitaxel, followed by durvalumab as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
Imfinzi (durvalumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized durvalumab in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) or durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).